CD44 and neoplasm: In this regard, we examined the subsets of memory CD8+ T cells (naïve CD44lowCD62LhighCD8+ T cells, CD8+ TN; central memory CD44highCD62LhighCD8+ T cells, CD8TCM; effector memory CD44highCD62LlowCD8+ T cells, CD8+ TEM) 35 days after tumor challenge using FACS analysis based on CD44 and CD62L markers.